Characterization of Agouti-Related Protein Binding to Melanocortin Receptors
Ying-kui Yang,
Darren A. Thompson,
Chris J. Dickinson,
Jill Wilken,
Greg S. Barsh,
Stephen B. H. Kent and
Ira Gantz
Departments of Surgery (Y-k.Y., I.G.) and Pediatrics (C.J.D.)
University of Michigan Medical Center Ann Arbor, Michigan
48109-0682
Howard Hughes Medical Institute (G.S.B.)
Stanford University School of Medicine Stanford, California
94305 Gryphon Sciences (D.A.T., J.W., S.B.H.K.), South
San Francisco, California 94080
 |
ABSTRACT
|
---|
Agouti-related protein (AGRP) is a naturally
occurring antagonist of melanocortin action that is thought to play an
important role in the hypothalamic control of feeding behavior. The
exact mechanism of AGRP and Agouti protein action has been difficult to
examine, in part because of difficulties in producing homogeneous forms
of these molecules that can be used for direct binding assays. In this
report we describe the application of chemical protein synthesis to the
construction of two novel AGRP variants. Examination of the biological
activity of the AGRP variants demonstrates that a truncated variant,
human AGRP(87132), a 46-amino acid variant based on the
carboxyl-terminal cysteine-rich domain of AGRP, is equipotent to an
111-amino acid variant, mouse [Leu127Pro]AGRP (mature AGRP minus its
signal sequence), in its ability to dose dependently inhibit
-MSH-generated cAMP generation at the cloned melanocortin receptors.
Furthermore, deletion of the amino-terminal portion of the full-length
variant did not alter the MCR subtype specificity of AGRP(87132).
Finally, iodination of human AGRP(87132) provided a useful reagent
with which the binding properties of AGRP could be analyzed. In both
conventional and photoemulsion binding studies
[125I]AGRP(87132) was observed only to bind
to cells expressing melanocortin receptors MC3R, MC4R, and MC5R. These
results demonstrate that the residues critical for receptor binding,
-MSH inhibition, and melanocortin receptor subtype specificity are
all located in the carboxyl terminus of the molecule. Because
[Nle4,
D-Phe7] (NDP)-MSH
displaces the binding of [125I]AGRP(87132)
to MCRs and AGRP(87132) displaces the binding of
[125I]NDP-MSH, we conclude that these
molecules bind in a competitive fashion to melanocortin receptors.
 |
INTRODUCTION
|
---|
Agouti-related protein (AGRP) is a recently discovered
neuropeptide that has generated intense interest because a growing body
of evidence indicates it has a major role in the regulation of
mammalian feeding behavior (1, 2). AGRP was identified by virtue of its
sequence similarity to the product of the Agouti coat color
gene, a paracrine signaling molecule normally expressed in skin whose
transient expression during hair growth leads to the barring of coat
fur in rodents (e.g. dark hair with a subapical yellow band)
(3).
Ubiquitous expression of Agouti, which occurs in mice that carry
mutations in the 5'-flanking region of the Agouti gene,
gives rise to pleiotropic effects including a yellow coat, obesity,
insulin resistance, increased body length, and premature infertility
(4). The recent identification of AGRP indicates that the obesity and
diabetes caused by ectopic Agouti expression are likely
explained by its ability to mimic AGRP, since ubiquitous expression of
AGRP in transgenic mice causes an increased weight gain and body length
phenotype identical to that produced by ubiquitous expression of
Agouti (2). Structurally, however, the similarity between
Agouti and AGRP is confined almost entirely to their 40-residue
carboxyl termini where a total of 20 residues, including 10 cysteine
residues, are identical (Fig. 1
).

View larger version (41K):
[in this window]
[in a new window]
|
Figure 1. Amino Acid Sequence Alignments of Mouse and Human
AGRP and Mouse and Human Agouti Protein
Conserved C-terminal cysteine residues are enclosed in
boxes. The presumed signal sequence cleavage position is
denoted by , which also denotes the N terminus of mouse
[Leu127Pro]AGRP. Denotes the start of the C-terminal sequence
that is AGRP(87132). Note that the C-terminal portion of mouse and
human AGRP are identical except for position 127 in the human sequence
(126 of the mouse sequence) where Pro is present in the human sequence
and Leu in the mouse sequence. m, Mouse; h, human.
|
|
Both Agouti and AGRP have been shown to antagonize the action of
melanocortin peptides such as
-MSH and ACTH at specific melanocortin
receptor subtypes. Agouti potently antagonizes the action of
melanocortins at the melanocyte melanocortin receptor (MC1R),
adrenocortical ACTH receptor (MC2R), and the MC4R (5, 6). In contrast,
we recently demonstrated that AGRP primarily antagonizes the MC3R and
MC4R (2), each of which is expressed in areas of the hypothalamus
implicated in feeding behavior (7, 8). Some or all of the growth and
weight gain phenotypes caused by Agouti or AGRP
are likely mediated via the MC4R, since mice carrying an MC4R knockout
mutation display obesity and metabolic abnormalities similar to those
caused by ubiquitous expression of Agouti or
AGRP (2, 9).
Several explanations have been proposed to explain the mechanism of
Agouti or AGRP action, including simple competitive antagonism (10),
inverse agonism (11), or activation of an effector other than adenylate
cyclase (12). Distinguishing among these alternatives has been
complicated, in part, by the absence of direct assays for Agouti or
AGRP binding, since a hallmark of competitive antagonism is the ability
of agonist to displace labeled antagonist. We have recently
demonstrated that an epitope-tagged form of Agouti protein interacts
directly with the MC1R in an overlay experiment, but these assays are
not quantitative and so do not allow a comparison among different
receptors or antagonists (13).
Our previous studies were carried out with preparations of recombinant
AGRP that were partially purified and heterogeneous in length. In
contrast to recombinant techniques, chemical protein synthesis can be
used to make a homogeneous preparation of defined molecular structure
that can be chemically labeled and derivatized and that can serve as a
substrate for structure-function analyses. Here we describe the
application of two novel chemically synthesized AGRP variants to
studies directed at understanding the mechanism of AGRP action. The
first, AGRP(87132), is a 46-residue peptide containing five disulfide
bonds formed by folding the C-terminal portion of human AGRP. We
demonstrate that radioiodinated AGRP(87132) can be used as a
high-affinity tracer to directly quantitate cell surface AGRP binding.
The second variant, mouse [Leu127Pro]AGRP, is a 111-amino acid AGRP
molecule (mature AGRP minus its 20-amino acid signal sequence) that was
made by joining the N-terminal residues 2185 of mouse AGRP to human
AGRP(87132) by native chemical ligation (14). In these studies we
address three important issues: 1) the bioactivity of the synthetic
AGRPs; 2) the binding properties of AGRP; and 3) the demonstration that
AGRP(87132) maintains the activity of full-length AGRP.
 |
RESULTS
|
---|
Effect of Mouse [Leu127Pro]AGRP and Human AGRP(87132) on
-MSH-Stimulated cAMP Generation in Cell Lines Transfected with
Melanocortin Receptors
To help verify the biological activity of the chemically
synthesized proteins, we examined the ability of the proteins to
inhibit
-MSH-stimulated cAMP generation. We have shown previously
that partially purified recombinant human AGRP is a potent antagonist
of the hMC3R and hMC4R, but has little or no effect on the hMC1R,
hMC2R, or hMC5R. Figure 2
, AE,
demonstrates that chemically synthesized mouse [Leu127Pro]AGRP
potently inhibits the action of
-MSH at the hMC3R and hMC4R. With
increasing concentrations of mouse [Leu127Pro]AGRP, a progressive
rightward shift of the
-MSH dose-response curves is observed. Mouse
[Leu127Pro]AGRP was completely devoid of activity at the hMC1R and
hMC2R. However, at higher concentrations, mouse [Leu127Pro]AGRP had a
modest inhibitory effect on
-MSH action at the hMC5R. Schild
analysis performed by plotting a linear regression of the log
concentration of AGRP (x-axis) and log (DR-1) (y-axis) revealed a slope
of 0.94 and 0.96 for mouse [Leu127Pro]AGRP at the hMC3R and hMC4R,
respectively (Fig. 2
, D and E, insets) (15). Slopes
approaching unity indicate that mouse [Leu127Pro]AGRP has the
characteristics of a competitive antagonist of
-MSH action at the
hMC3R and hMC4R. Inhibitory constants (Ki) for mouse
[Leu127Pro]AGRP derived from this Schild analysis revealed a
Ki of 4.3 ± 0.6 nM at the hMC3R and
a Ki of 2.5 ± 0.25 nM at the hMC4R (Table 1
).
We next compared the pharmacological effects of the 111-residue mouse
[Leu127Pro]AGRP to those displayed by the 46-residue AGRP(87132) at
the various hMCR subtypes. AGRP(87132) had no effect at hMC1R or
hMC2R and only a minimal effect at the hMC5R. Schild analysis revealed
that AGRP(87132), like mouse [Leu127Pro]AGRP, is a competitive
antagonist (data not shown) with Ki values for inhibition
of
-MSH at the hMC3R and hMC4R of 3.3 ± 0.28 nM
and 2.6 ± 0.21 nM, respectively. We also examined
the effect of recombinant human AGRP Form A + B on
-MSH-stimulated
cAMP generation at the hMC4R (Fig. 2F
). Although the dose-response
curves for recombinant human AGRP Form A + B were not parallel, a
linear regression of the data revealed a slope of 0.94 and
Ki of 1.2 ± 0.17 nM (Fig. 2F
, inset). In contrast to chemically synthesized mouse
[Leu127Pro]AGRP, the Emax of
-MSH in the presence of
recombinant human AGRP Form A + B was about 10% below that observed in
the absence of this antagonist. Neither chemically synthesized nor
recombinant AGRP had an effect on cAMP accumulation when applied to
cells in the absence of agonist.
[125I][Nle4,
D-Phe7] (NDP)-MSH
Binding to Cell Lines Transfected with Melanocortin Receptors
Because the effects of AGRP on cAMP generation are an indirect
measure of antagonism, we measured the ability of chemically
synthesized or recombinant AGRP to inhibit the binding of NDP-MSH to
hMCR-expressing cells. Figure 3A
reveals that chemically synthesized
mouse [Leu127Pro]AGRP dose dependently displaces
[125I]NDP-MSH from the hMC3R, hMC4R, and hMC5R. The
displacement curve of [125I]NDP-MSH from the hMC5R was
shifted to the right as compared with the hMC3R and hMC4R. No
significant displacement was observed at the hMC1R (data not shown).
These binding studies are consistent with the actions of mouse
[Leu127Pro]AGRP and AGRP(87132) in the cAMP assays.
IC50 values for [125I]NDP-MSH displacement
are hMC1R>10-6 M, hMC3R = 17.4 ±
3.7 nM, hMC4R = 15.7 ± 4.1 nM,
hMC5R = 310.6 ± 18.7 nM. Figure 3B
compares the ability of mouse
[Leu127Pro]AGRP, AGRP(87132), and recombinant human AGRP Form A + B
to displace [125I]NDP-MSH from the hMC4R. The
displacement curves of baculovirus-produced human AGRP Form A + B and
chemically synthesized mouse [Leu127Pro]AGRP are identical, while the
curve of chemically synthesized AGRP(87132) is slightly shifted to
the left (3 times more potent). The IC50 for
recombinant human AGRP Form A + B was 13.4 ± 2.9
nM.

View larger version (32K):
[in this window]
[in a new window]
|
Figure 3. Displacement of Radioligand Binding from the Human
Melanocortin Receptors Stably Expressed in HEK-293 Cells
A, Displacement of [125I]NDP-MSH binding from the hMCR 3,
4, and 5 by chemically synthesized mouse [Leu127Pro]AGRP. B,
Comparison of the displacement of [125I]NDP-MSH binding
from the hMC4R by recombinant human AGRP Form A + B, chemically
synthesized mouse [Leu127Pro]AGRP, and AGRP(87132). C, Displacement
of [125I]AGRP(87132) binding from the hMCR 3, 4, and 5
by AGRP(87132). D, Displacement of [125I]AGRP(87132)
binding from the hMCR 3, 4, and 5 by NDP-MSH.
[125I]AGRP(87132) does not bind the hMC1R or hMC2R.
|
|
[125I]AGRP(87132) Binding to Cell Lines
Transfected with Melanocortin Receptors
Previous biochemical studies of Agouti protein have been
complicated by the lack of a radiolabeled derivative. In contrast, AGRP
has two tyrosine residues, both of which are present in its
carboxyl-terminal sequence. We were therefore able to take advantage of
the purity of chemically synthesized human AGRP(87132) to use
standard oxidative chemistries to generate a radiolabeled molecule that
exhibited specific binding to hMCR-expressing cells. In initial
autoradiographic experiments using slides coated with photoemulsion, we
asked whether tracer amounts of [125I]AGRP(87132) would
bind to HEK 293 cells that expressed equivalent levels of the different
melanocortin receptors (
2.5 x 105 per well). As
shown in Fig. 4
, [125I]AGRP(87132) only binds to cells
expressing the hMC3R, hMC4R, and hMC5R. No specific radioligand binding
was observed in wild-type cells or at the hMC1R or hMC2R (Fig. 4
and data not shown). The intensity of
the binding studies is consistent with the rank order of AGRP
inhibition noted in our functional studies (hMC4R = hMC3R >
hMC5R).

View larger version (132K):
[in this window]
[in a new window]
|
Figure 4. Representative Photomicrographs of
[125I]AGRP(87132) Binding to HEK 293 Cells Transfected
with hMCR 3, 4, and 5
Under bright field illumination (right) cells are seen
as outlines on a light background. Under dark field illumination
(left) the identical cells are seen. Under dark field,
cells binding [125I]AGRP(87132) are seen as white
elements in a surrounding dark background. Because of the absence of
binding, wild-type cells only appear as faint outlines. No binding was
observed in similar experiments with cells expressing the hMC1R and
hMC2R.
|
|
As a quantitative measure of binding, we examined the ability of
unlabeled AGRP(87132) to displace [125I]AGRP(87132)
from the hMC3R, hMC4R, and hMC5R-expressing cells (Fig. 3C
). Notably,
the displacement curves of [125I]AGRP(87132) from the
hMC3R and hMC4R are overlapping, which is consistent with our previous
functional and photoemulsion studies and indicate that AGRP(87132) is
essentially equipotent at the two receptor subtypes. The
IC50 values of [125I]AGRP(87132)
displacement by AGRP(87132) at the hMC3R = 11.2 ± 3.1
nM, hMC4R = 9.0 ± 1.7 nM, and
hMC5R = 25.6 ± 4.3 nM.
A hallmark of competitive binding is the ability of one ligand to
displace the other, and vice versa. As indicated in Fig. 3A
, AGRP(87132) can displace [125I]NDP-MSH from the
hMC3R, hMC4R, and hMC5R. The converse is also true as shown in Fig. 3D
, which examines the ability of NDP-MSH to displace
[125I]AGRP(87132). The IC50 values of
[125I]AGRP(87132) displacement by NDP-MSH are as
follows: at the hMC3R = 1.9 ± 0.15 nM;
hMC4R = 3.75 ± 0.1 nM; and hMC5R =
11.2 ± 2.1 nM. The [125I]NDP-MSH and
[125I]AGRP(87132) displacement data and the cAMP data
reveal a hierarchy of melanocortin receptor subtype sensitivity to AGRP
such that hMC3R = hMC4R > hMC5R.
 |
DISCUSSION
|
---|
The identification of AGRP has added additional complexity to our
attempts to understand weight homeostasis. Recent pharmacological and
anatomical data have further strengthened the link between
melanocortins and weight control and indicate that melanocortins act
downstream of the fat hormone leptin (16, 17, 18, 19). Levels of AGRP mRNA
exhibit up to 10-fold alterations in different obesity models (1, 2)
and, therefore, as a naturally occurring orexigenic agent that
antagonizes melanocortins, AGRP may represent a unique target for
antiobesity drug development.
While our previous studies of the action of baculovirus-produced AGRP
allowed us to determine some aspects of this regulatory proteins
action, our inability to produce highly purified product led us to
consider an alternative approach. Chemical protein synthesis uses
native chemical ligation of unprotected synthetic peptide segments in
aqueous solution, followed by folding/disulfide formation to give the
functional protein molecule (14). Our present experiments demonstrate
that the techniques of chemical protein synthesis can be used to
rapidly produce highly purified, biologically active AGRP molecules in
amounts of tens of milligrams in a convenient and straightforward
fashion. In the present correspondence we capitalized on the use of
these synthetic techniques to build upon our previous observations of
AGRP. The availability of highly purified AGRP protein variants allowed
us not only to readily develop an AGRP radioligand with which the site
of AGRP action could be explored, but also enabled us to perform more
detailed pharmacological analysis of this molecule.
Both chemically synthesized mouse [Leu127Pro] AGRP and
AGRP(87132) have similar inhibitory potency and efficacy as
baculovirus-produced human AGRP Form A + B. In cAMP assays
[Leu127Pro] AGRP, AGRP(87132), and recombinant human AGRP Form A +
B are essentially equipotent at inhibiting the hMC4R. Both chemically
synthesized variant AGRP molecules were also found to display a similar
nanomolar range of activity as previously observed for human
recombinant Form A + B at the hMC3R (2). Like recombinant human Form A
+ B, both chemically synthesized AGRP variants had only minimal
activity at the hMC5R, and neither displayed any inhibitory activity at
the hMC1R or the hMC2R. AGRP(87132) was only slightly more potent
than either longer synthetic or recombinant forms of AGRP in displacing
[125I]NDP-MSH from the hMC4R.
Having demonstrated the biological activity of the chemically
synthesized AGRP variants, we used AGRP(87132) to further study the
actions of this protein. Our ability to radiolabel AGRP(87132) with
125I allowed us to directly study AGRP(87132) binding.
[125I]AGRP(87132) bound only to those heterologous cell
lines expressing melanocortin receptor subtypes susceptible to AGRP
inhibition in cAMP assays and at which [125I]NDP-MSH was
displaced by mouse [Leu127Pro]AGRP (Fig. 3
). Typical displacement
curves appear to indicate that the iodination process did not alter the
biological activity of AGRP(87132). The finding that the displacement
of [125I]AGRP(87132) from the hMC5R was shifted to the
right is consistent with the decreased potency of AGRP at this receptor
subtype observed in cAMP assays.
A persistent controversy that has existed regarding the action of
Agouti protein is whether it has effects independent of its antagonism
of
-MSH (11, 12, 13). Much of this speculation is based on the sequence
similarity between agouti protein, and cone snail (conotoxins) and
spider (plectoxins) toxins. These toxins, which affect calcium
channels, contain a cysteine-rich motif that can be closely aligned
against 10 cysteine residues present in the C terminus of both Agouti
and AGRP (Fig. 1
). While some of the effects of Agouti in the absence
of
-MSH may be explained by its ability to act as inverse agonist,
it has been suggested that a separate agouti receptor may exist (20, 21). This controversy has been approached by examining the action of
Agouti on melanoma cell lines lacking the MC1R (13). More recently,
epitope-tagged Agouti has been used (22). However, this matter has been
somewhat difficult to study since a radiolabeled Agouti has not been
developed. Because of this controversy we used the novel radioligand
[125I]AGRP(87132) to examine the binding sites of AGRP.
Both conventional binding studies and photoemulsion studies indicate
that [125I]AGRP(87132) only binds to melanocortin
receptors demonstrated to be susceptible to AGRP inhibition in cAMP
assays. This does not, however, exclude the possibility that an
endogenous cell type that expresses a native hMC3R, hMC4R, or hMC5R may
also possess additional binding sites.
The competitive pattern of AGRP inhibition of melanocortins binding to
the MC3R and MC4R observed in the present studies does not necessarily
imply that AGRP and melanocortin agonist occupy the same site on the
receptor. It is possible that the two ligands simply influence each
others binding through an allosteric mechanism. In fact, there is no
significant sequence similarity between melanocortins and AGRP,
although this does not exclude some similarity on the basis of
three-dimensional structure. Future receptor mutagenesis studies using
our novel radioligand [125I]AGRP(87132) and the
radioligand [125I]NDP-MSH should be helpful in this
respect.
Although AGRP(87132) was approximately 3-fold more potent than
mouse [Lue127Pro] AGRP in its ability to displace
[125I]MSH-MSH from hMC4R-expressing cells, the
antagonists were equipotent in their ability to inhibit
-MSH-induced
cAMP accumulation mediated by the hMC4R. Regardless of the reasons for
this apparent difference, these results indicate that the structural
determinants for both MCR binding and melanocortin antagonism are
located within the cysteine-rich C-terminal domain. Furthermore,
AGRP(87132) retains the pattern of melanocortin receptor selectivity
displayed by the full-length molecule. Further truncation and other
manipulations of human AGRP(87132) will help identify its minimally
active form, and modification of residues within this fragment should
provide insight into the determinants of receptor subtype
selectivity.
In summary, these studies demonstrate the ability to chemically
synthesize biologically active AGRP variants. These studies also
demonstrate that AGRP(87132), a variant lacking the N terminus of
AGRP and consisting of only the C-terminal cysteine-rich AGRP module,
retains the biological activity of full-length AGRP. Finally, these
studies describe the AGRP radioligand,
[125I]AGRP(87132), and demonstrate the binding of this
radioligand directly to melanocortin receptor protein.
[125I]AGRP(87132) should be a helpful tool for
anatomical studies of the natural sites of AGRP binding, development of
an AGRP RIA, and identification of small molecule antagonists of AGRP
interaction with the melanocortin receptors. The latter compounds could
have potential applications as regulators of human feeding
behavior.
 |
MATERIALS AND METHODS
|
---|
Mouse [Leu127Pro]AGRP and AGRP(87132) Synthesis
Peptides were synthesized by Boc chemistry using manual stepwise
solid-phase peptide synthesis as previously described (23). The
46-amino acid polypeptide corresponding to the C-terminal module, human
AGRP(87132), was assembled on Thr-OCH2-Pam-resin
(Perkin-Elmer Applied Biosystems, Foster City, CA). The
N-terminal basic segment, mouse AGRP 2185, was assembled on a
thioester resin. Peptides were cleaved from the resin with hydrogen
fluoride containing 510% p-cresol (Fluka, Buchs,
Switzerland) for 1 h at 0 C, lyophilized, and then purified using
reversed phase HPLC on C4 columns (Vydac, Murrieta, CA) with water
(0.1% trifluoroacetic acid)/acetonitrile (0.1% trifluoroacetic
acid) gradients. The molecular weights of these peptides were confirmed
by electrospray ionization mass spectrometry (Perkin-Elmer
SCIEX, Foster City, CA). To generate the full-length construct,
purified mouse AGRP(2185) thioester and human AGRP(87132) were
dissolved in 6 M guanidine hydrochloride and 200
mM phosphate (pH 7.0) containing 1% thiophenol at a
concentration of 24 mM and stirred overnight. Under these
conditions native chemical ligation joined the two peptides to
form full-length mouse [Leu127Pro]AGRP(21131), appearing as a new
peak on analytical HPLC with mol wt indicative of segment condensation
by peptide bond formation [observed: 12,397.4 ± 1.50;
calculated: 12,394.5 (average isotopes)]. Ligated peptides were then
fully reduced by incubating 1 h with 20% ß-mercaptoethanol,
purified by HPLC, and lyophylized [24 mg mouse AGRP(2185)]
thioester + 16.9 mg human AGRP(87132) yielded 14.3 mg mouse
[Leu127Pro]AGRP. Protein folding of human AGRP(87132) and mouse
[Leu127Pro]AGRP was initiated by dissolving the lyophilized peptide
in a solution of 2 M guanidine hydrochloride and 100
mM Tris (pH 8.0) containing 8 mM cysteine and 1
mM cystine (Fluka), and stirring overnight. The folded
proteins were then purified by HPLC and lyophilized. Human
AGRP(87132) (138.2 mg) (reduced) yielded 52.5 mg AGRP(87132)
(oxidized); 14.3 mg [Leu127Pro]AGRP (reduced) yielded 4.7 mg
[Leu127Pro]AGRP (oxidized). Two-dimensional nuclear magnetic
resonance studies of AGRP(87132) confirmed the existence of a single
homogeneous folded state (K. Bolin, J. Trulson, and G. L.
Millhauser, unpublished results). This observation was supported by the
formation of a sharp peak on analytical reverse phase HPLC eluting
earlier than the reduced state, and the loss of 10 mass units by
electrospray ionization mass spectrometry, which is consistent with the
formation of five disulfides in the oxidized form (AGRP(87132)
observed: 5,191.1 ± 1.05; calculated: 5,191.2 (average isotopes);
mouse [Leu127Pro]AGRP observed: 12,384.9 ± 1.11; calculated:
12,383.5 (average isotopes).
Baculovirus-produced recombinant human AGRP Form A + B was produced and
partially purified as previously described (2, 24). Form A + B refers
to nonhomogeneous fractions of recombinant AGRP that run closely
together on Western blot (2). Form A consists of mature AGRP minus its
signal sequence of 20 amino acids, and Form B contains several
fragments cleaved after residues 46, 48, or 50.
cAMP Assays
cAMP generation was measured using a competitive binding assay
kit (TRK 432, Amersham, Arlington Heights, IL) according to a
standardized protocol (6). Heterologous cell lines stably expressing
the human (h) melanocortin receptors that have been previously
described were used in these assays (6). For assays, culture media were
removed and cells were incubated with 0.5 ml Earles balanced salt
solution that contained AGRP and melanocortin agonist for 30 min at 37
C in the presence of 10-3 M
isobutylmethylxanthine. The reaction was stopped by adding ice-cold
100% ethanol (500 µl/well). The cells in each well were scraped and
transferred to a 1.5-ml tube and centrifuged for 10 min at 1900 x
g, and the supernatant was evaporated in a 55 C water bath
with prepurified nitrogen gas. cAMP content was measured according to
instructions accompanying the assay kit.
-MSH and human ACTH 139
were obtained from Peninsula Laboratories, Inc. (Belmont, CA). Each
experiment was performed a minimum of three times with duplicate wells.
The mean value of the dose-response data were fit to a sigmoid curve
with a variable slope factor using the nonlinear squares regression in
Graphpad Prism (Graphpad Software, San Diego, CA). EC50
values determined from these fits were used for plotting Schild
analysis linear regressions. pA2 values were derived from
the y = 0 intercept of the Schild plot of the log of dose ratio
minus one (log DR-1) as previously described (6). Ki values
were determined as the negative log of the pA2. All
statistical analyses represent the mean of the data ±
SE.
Radioiodination
NDP-MSH, a long acting superpotent melanocortin agonist, was
obtained from Peninsula Laboratories, Inc. (Belmont, CA) (25).
[125I]NDP-MSH and [125I]AGRP(87132) were
prepared by a modification of a chloramine-T method previously
described (26). 125I-labeled Na (0.5 mCi) (Amersham) was
added to 20 µg of either NDP-MSH or AGRP(87132) in 5 µl of 50
mM sodium phosphate buffer (pH 7.4). Ten microliters of a
2.4 mg/ml solution of chloramine T (Sigma Chemical Co., St. Louis, MO)
in 50 mM sodium phosphate (pH 7.4) were added for 15 sec,
and the reaction was stopped with 50 µl of a 4.8 mg/ml solution of
sodium metabisulfite (Sigma). The reaction mixture was then diluted in
800 µl of 50 mM ammonium acetate (pH 5.8) and purified by
reverse phase chromatography. BSA (100 µl of a 2% solution) was
added to all fractions containing radioactivity.
Binding Experiments
After removal of media the cells were washed twice with MEM and
then preincubated with AGRP in 0.5 ml MEM (Life Technologies,
Gaithersburg, MD) containing 0.2% BSA for 30 min before incubation
with radioligand. Binding experiments were performed using conditions
previously described (6). [125I]NDP-MSH (3 x
105 cpm;
61 fmol) or 3 x 105 cpm
125I-AGRP(87132) (
55 fmol) were used. Binding
reactions were terminated by removing the media and washing the cells
twice with MEM containing 0.2% BSA. The cells were lysed with 0.1
N NaOH 1% Triton X-100, and the radioactivity in the
lysate was quantified in an analytical
-counter. Nonspecific binding
was determined by measuring the amount of 125I-label
remaining bound in the presence of 10-5 M
unlabeled ligand, and specific binding was calculated by subtracting
nonspecifically bound radioactivity from total bound radioactivity.
Typically, total binding of [125I]AGRP(87132) was about
13.5 ± 1.3 x 104 cpm, and nonspecific binding
was 3.0 ± 0.4 x 103 cpm. For photoemulsion
studies, the binding assays were performed directly on a chambered
microscope slides (SlideFlask, NUNC, Roskilde, Denmark). Approximately
105 cells were placed on each slide and allowed to grow for
12 h. After binding experiments were performed, slides were fixed
with gluteraldehyde and dried. Slides were then dipped in Kodak NTB2
photoemulsion (Eastman Kodak Co., New Haven, CT) and exposed for 3 days
before being developed, examined, and photographed using a Leica DMRB
microscope (Leica, Inc., Deerfield, IL).
 |
FOOTNOTES
|
---|
Address requests for reprints to: Ira Gantz, M.D., 6504 MSRB I, 1150 West Medical Center Drive, Ann Arbor, Michigan 48109-0682. E-mail:
IGantz{at}UMich.edu
This work was supported by a Veterans Administration Merit Review Award
(I.G.), funds from the University of Michigan Gastrointestinal Peptide
Research Center (NIH Grant P30 DK-34933), RO1 DK-47398 (C.J.D.), and
RO1 DK-28506 (G.S.B). G.S.B is an Associate Investigator of the Howard
Hughes Medical Institute.
Received for publication July 7, 1998.
Revision received September 15, 1998.
Accepted for publication September 18, 1998.
 |
REFERENCES
|
---|
-
Shutter JR, Graham M, Kinsey AC, Scully S, Lüthy R,
Stark KL 1997 Hypothalamic expression of ART, a novel gene related to
agouti, is up-regulated on obese and diabetic
mutant mice. Gene Dev 11:593602[Abstract]
-
Ollmann MM, Wilson BD, Yang Y-K, Kerns JA, Chen Y, Gantz I,
Barsh GS 1997 Agouti-related protein is an endogenous antagonist of the
melanocortin-4 receptor in vitro and in vivo.
Science 278:135138[Abstract/Free Full Text]
-
Bultman SJ, Michaud EJ, Woychik RP 1992 Molecular
characterization of the mouse agouti locus. Cell 71:11951204[Medline]
-
Leibel RL, Chung WK, Chua SC 1997 The molecular genetics of
rodent single gene obesities. J Biol Chem 272:3193731940[Free Full Text]
-
Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T,
Luther M, Chen W, Woychik RP, Wilkison WO, Cone RD 1994 Agouti protein
is an antagonist of the melanocyte-stimulating hormone receptor. Nature 371:799802[CrossRef][Medline]
-
Yang Y-K, Ollmann MM, Wilson BD, Dickinson C, Yamada T, Barsh
GS, Gantz I 1997 Effects of recombinant ASIP on melanocortin action.
Mol Endocrinol 11:274280[Abstract/Free Full Text]
-
Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ,
DelValle J, Yamada T 1993 Molecular cloning, expression, and gene
localization of a fourth melanocortin receptor. J Biol Chem 268:1517415179[Abstract/Free Full Text]
-
Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD 1994 Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine
and autonomic control circuits in the brain. Mol Endocrinol 8:12981308[Abstract]
-
Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q,
Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ,
Campfield LA, Burn P, Lee F 1997 Targeted disruption of the MC4R
results in obesity in mice. Cell 88:131141[Medline]
-
Willard DH, Bodnar W, Harris C, Kiefer L, Nichols JS,
Blanchard S, Hoffman C, Moyer M, Burkhart W, Weiel J, Luther MA,
Wilkison WO, Rocque WJ 1995 Agouti structure and function:
characterization of a potent
-melanocyte stimulating hormone
receptor antagonist. Biochemistry 34:1234112346[Medline]
-
Siegrist W, Drozdz R, Cotti R, Willard DH, Wilkison WO, Eberle
AN 1997 Interactions of
-melanotropin and agouti on B16 melanoma
cells: evidence for inverse agonism of agouti. J Recept Signal
Transduct Res 17:7598[Medline]
-
Kim JH, Kiefer LL, Woychik RP, Wilkison WO, Truesdale A,
Ittoop O, Willard D, Nichols J, Zemel MB 1997 Agouti regulation of
intracellular calcium: role of melanocortin receptors. Am J
Physiol 272:E379E384
-
Ollmann MM, Lamoreux ML, Wilson BD, Barsh GS 1998 Interaction
of agouti protein with the melanocortin 1 receptor in vitro
and in vivo. Genes Dev 12:316330[Abstract/Free Full Text]
-
Dawson PE, Muir TW, Clark-Lewis I, Kent SBH 1994 Synthesis of
proteins by native chemical ligation. Science 266:776779[Medline]
-
Kenakin TP (ed) 1987 Drug antagonism. In: Pharmacologic
Analysis of Drug-Receptor Interaction. Raven Press, New York, pp
221236
-
Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD 1997 Role of
melanocortinergic neurons in feeding and the agouti obesity syndrome.
Nature 385:165168[CrossRef][Medline]
-
Seeley RJ, Yagaloff KA, Fisher SL, Burn P, Thiele TE, Van Dijk
G, Baskin DG, Schwartz MW 1997 Melanocortin receptors in leptin
effects. Nature 390:349[CrossRef][Medline]
-
Thronton JE, Cheung CC, Clifton DK, Steiner RA 1997 Regulation
of hypothalamic POMC mRNA by leptin in ob/ob mice. Endocrinology 138:50635066[Abstract/Free Full Text]
-
Håkansson M-L, Brown H, Ghilardi N, Skoda RC, Meister B 1998 Leptin receptor immunoreactivity in chemically defined target neurons
of the hypothalamus. J Neurosci 18:559572[Abstract/Free Full Text]
-
Sakai C, Ollmann M, Kobayashi T, Abdel-Malek Z, Muller J,
Vierira WD, Imokawa G, Barsh GS, Hearing VJ 1997 Modulation of murine
melanocyte function in vitro by agouti signal protein. EMBO J 16:35443552[Abstract/Free Full Text]
-
Conklin BR, Bourne HR 1993 Muse coat colour reconsidered.
Nature 364:110[Medline]
-
Siegrist W, Willard DH, Wilkison WO, Eberle AN 1996 Agouti
protein inhibits growth of B16 melanocma cells in vitro by
acting through melanocortin receptors. Biochem Biophys Res Commun 218:171175[CrossRef][Medline]
-
Schnolzer M, Alewood P, Jones A, Alewood D, Kent SBH 1992 In
situ neutralization in Boc-chemistry solid phase peptide synthesis.
Rapid, high yield assembly of difficult sequences. Int J Pept Protein
Res 40:180193[Medline]
-
Potenza MN, Lerner MR 1992 A rapid quantitative bioassay for
evaluating the effects of ligands upon receptors that modulate cAMP
levels in a melanophore cell line. Pigment Cell Res 5:372378[Medline]
-
Hadley ME, Anderson B, Heward CB, Sawyer TK, Hruby VJ 1981 Calcium-dependent prolonged effects on melanophores of [4-norleucine,
7-D-phenylalanine]-
-melanotropin. Science 213:10251027[Medline]
-
Tatro JB, Reichlin S 1987 Specific receptors for
alpha-melanocyte-stimulating hormone are widely distributed in tissues
of rodents. Endocrinology 121:19001907[Abstract]